Findings from the phase III HER2CLIMB-02 trial presented at the San Antonio Breast Cancer Symposium showed that the addition of tucatinib (Tukysa) to trastuzumab emtansine (T-DM1, Kadcyla) extended ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback